Protagonist Therapeutics Announces $300 Million Share Repurchase Program

Protagonist Therapeutics, a biopharmaceutical company, has announced a significant share repurchase program aimed at enhancing shareholder value. The company's board of directors has authorized the repurchase of up to $300 million worth of the company's outstanding common stock.

Protagonist Therapeutics, based in Newark, California, intends to fund the share repurchase program from its existing financial resources, including cash, cash equivalents, and marketable securities, as well as future royalty and milestone payments. As of June 30, 2026, the company had $849.5 million in cash, cash equivalents, and marketable securities, excluding a $200 million opt-out payment and a $75 million milestone payment it earned in August 2026 under its collaboration agreement with Takeda Pharmaceutical Company Limited. The company expects to receive the opt-out payment in the fourth quarter of 2026.

The repurchase program, which does not obligate Protagonist to acquire any specific number of shares, will be executed based on various factors, including market conditions, the trading price of the company's common stock, the timing and amount of future royalty and milestone payments, and general market conditions. Stock repurchases may be made from time to time through open market transactions or other methods, including the use of a trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Protagonist Therapeutics has a robust pipeline of product candidates, including ICOTYDE™ (icotrokinra) and MIMRYLO™ (rusfertide), both of which have generated significant royalties and milestones from global commercial partnerships. ICOTYDE, licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. It was launched in the U.S. in March 2026 for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis, and Crohn's disease. MIMRYLO, licensed to Takeda Pharmaceutical Company Limited, is approved in the U.S. for the treatment of erythrocytosis in adults with primary polycythemia (PV).

The company's strategy includes the discovery and development of new peptide-based therapies through its proprietary platform. Recent developments include the launch of ICOTYDE and the initiation of clinical and preclinical programs for an oral IL-17 antagonist peptide, anti-obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin discovery programs.

Protagonist Therapeutics emphasizes that the repurchase program is not a guarantee of future performance and is subject to market and other uncertainties. The company continues to focus on the development and commercialization of its pipeline of product candidates and the potential to generate further value for shareholders through this and other initiatives.